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S U M M A R Y
Tuberculosis (TB) is now the most common infectious cause of death worldwide. In 2014, an estimated
9.6 million people developed active TB. There were an estimated three million people with active TB
including 360 000 with multidrug-resistant TB (MDR-TB) who were not diagnosed, and such people
continue to fuel TB transmission in the community. Accurate data on the actual burden of TB and the
transmission risk associated with mass gatherings are scarce and unreliable due to the small numbers
studied and methodological issues. Every year, an estimated 10 million pilgrims from 184 countries
travel to the Kingdom of Saudi Arabia (KSA) to perform the Hajj and Umrah pilgrimages. A large majority
of pilgrims come from high TB burden and MDR-TB endemic areas and thus many may have undiagnosed
active TB, sub-clinical TB, and latent TB infection. The Hajj pilgrimage provides unique opportunities for
the KSA and the 184 countries from which pilgrims originate, to conduct high quality priority research
studies on TB under the remit of the Global Centre for Mass Gatherings Medicine. Research opportunities
are discussed, including those related to the deﬁnition of the TB burden, transmission risk, and the
optimal surveillance, prevention, and control measures at the annual Hajj pilgrimage. The associated
data are required to develop international recommendations and guidelines for TB management and
control at mass gathering events.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Tuberculosis (TB) was declared a global emergency by the
World Health Organization (WHO) in 1993.1 The latest 2015 WHO
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).for all public health authorities.2 In 2014, TB was responsible for
1.5 million deaths, making it the most common infectious cause of
death worldwide. An estimated 9.6 million people developed
active TB (5.4 million men, 3.2 million women, and 1.0 million
children). Multidrug-resistant TB (MDR-TB) is now widespread
with an estimated 480 000 cases. There were an estimated three
million people with active TB including 360 000 with MDR-TB who
were not diagnosed and remained untreated, continuing to fuel TB
transmission in the community. The UN Sustainable Development
Goals (SDGs) include ending the TB epidemic by 2030 as a speciﬁc
goal.3 The WHO post-2015 End TB Strategy adopted by the World
Health Assembly in May 2014,4 has two speciﬁc targets: (1) a 50%ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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(2) an overall 90% reduction in incidence and 95% reduction in
mortality by 2035.
The ease of international travel and migration are two of several
factors that are responsible for the spread of TB across the world.5–8
Every year, millions of people travel to sporting9,10 and religious
events,11 where the mass gathering of people is conducive to the
transmission of a range of infectious diseases, including TB.12,13
Developing an accurate evidence base to optimize surveillance,
screening, transmission risk, treatment, prevention, and control
measures for TB at mass gathering events is an important priority,
and will go a long way towards achieving the WHO post-2015 End TB
Strategy goals.4
2. Mass gatherings and TB transmission
When the FIFA World Cup Football event in 2010 was hosted by
South Africa – a high TB and MDR-TB prevalence country – there
was widespread concern among global public health authorities of
the spread of TB between attendees and the exportation of MDR-TB
outside South Africa.14,15 There is no existing global consensus or
scientiﬁc evidence base for the most effective public health
measures to reduce TB transmission at mass gathering events,
either within the host country or in the countries from which the
attendees originate. These data are required to develop optimal TB
surveillance, screening, treatment, prevention, and control mea-
sures for mass gathering events, to protect the attendees and the
local population of the host country.
Obtaining an accurate scientiﬁc evidence base on the burden of
TB and risk of transmission at mass gatherings is difﬁcult due to
operational and logistical difﬁculties in conducting cross-sectional
and longitudinal cohort studies. Furthermore, since TB is a chronic
disease, clinical manifestations of new cases of active TB only
become evident months after the mass gathering event. In light of
the continuing global TB emergency,2 is important to deﬁne the
burden of TB (active TB, sub-clinical TB, and latent TB infection
(LTBI)), the transmission risk, and the transmission dynamics of
drug-sensitive and drug-resistant Mycobacterium tuberculosis
strains at mass gathering events.
Conducting research at mass gatherings requires effective
collaboration between local organizers of the mass gathering event
and international stakeholders. This should include making
available the funding required to conduct a range of priority
studies, examples of which are listed in Table 1. The collaboration
should include the development of pre-speciﬁed protocols for
research and logistics planning, and have close involvement with
the WHO and national ministries of health. This collaborative
approach will enable the provision of resources and infrastructure
for screening and monitoring of large cohorts of travellers and
local populations before travel, during the event, and after return
home. It will also facilitate the translation of the evidence base
into policy and practice and the publication of guidelines and
recommendations.
3. Opportunities for conducting TB research at mass gatherings
The Global Centre for Mass Gatherings Medicine (GCMGM) has
its headquarters at the Ministry of Health in Riyadh, Kingdom of
Saudi Arabia (KSA), and is linked to a virtual network of other WHO
collaborating centres for mass gatherings and academic and public
health institutions.16 It provides a unique consortium of multidis-
ciplinary expertise to conduct research on a range of public health
issues and to gather the most appropriate evidence base for use by
countries hosting mass gathering events. The formal discipline of
Mass Gatherings Medicine was launched at the World Health
Assembly of Ministers of Health in Geneva in May 2014.16,17 Withrecent advances in technology, such as the availability of rapid
screening tests for LTBI and active pulmonary TB and for the
identiﬁcation of drug-resistant strains of M. tuberculosis,18,19
unique opportunities now present for conducting TB research
studies on cohorts of attendees at mass gatherings.
The KSA is particularly prone to the importation and exporta-
tion of TB because of the constant ﬂow throughout the year of huge
numbers of migrant workers and pilgrims from high TB burden
countries. Every year, an estimated 10 million pilgrims from
184 countries travel to the holy cities of Makkah and Madinah in
the KSA to perform the religious rites of the Hajj and Umrah
pilgrimages.11 A large majority of pilgrims come from high TB
burden areas. In addition, two million pilgrims come from other
regions of the KSA where TB and MDR-TB are important public
health issues among both the immigrant and indigenous popula-
tions.20–25 Screening for TB or LTBI before entry into the KSA is not
a visa prerequisite for pilgrims. Since many pilgrims come from
high TB endemic countries,2 it is likely that many pilgrims will
have undiagnosed active TB, sub-clinical TB, or LTBI. If the KSA and
the 184 countries from which the pilgrims originate are to achieve
the WHO post-2015 End TB Strategy goals,4 it is important to
deﬁne the burden of active TB and LTBI, the transmission risk to
both pilgrims and KSA residents, and the transmission dynamics
of drug-sensitive and drug-resistant M. tuberculosis strains. This
scientiﬁc evidence base is required in order to develop optimal
surveillance, screening, treatment, prevention, and control mea-
sures for pilgrims and the local resident population of the KSA.
4. Populations at risk of TB during the Hajj
A range of respiratory tract pathogens, including M. tuberculosis
and microbes resistant to antibiotics, are transmitted during the
Hajj pilgrimage.24–37 These are acquired by pilgrims during the
unavoidable frequent close contact with crowds during travel, at
points of entry, within living quarters, and whilst performing
religious rites. M. tuberculosis is spread by the aerosol route by
people with active pulmonary TB disease who cough or sneeze, and
thus transmission can occur amongst several groups of people: (1)
between pilgrims, (2) from pilgrims to KSA residents, (3) from KSA
residents to pilgrims, and (4) from pilgrims to their local
communities when they return to their home countries. Since
pilgrims stay in the KSA for only a few weeks, and the period
between ﬁrst infection with M. tuberculosis and developing active
TB disease is long, it is most likely that active TB disease diagnosed
during Hajj is either imported by the pilgrim or is due to
reactivation of LTBI. An estimated two billion people worldwide
have asymptomatic LTBI, thus many pilgrims with LTBI could
experience reactivation and progress rapidly to developing active
TB disease because of risk factors that compromise their immune
responses, such as stress, physical and mental exhaustion, old
age, poor nutrition, co-morbidities such as diabetes and chronic
pulmonary, liver, and renal diseases, immunosuppressive therapy,
or other causes of immune-compromise.38
5. TB prevalence in the holy cities
TB in the Makkah region (Jeddah, Makkah) is known to be an
important public health problem affecting all residents, Saudis and
non-Saudis. The cities have TB incidence rates up to four times the
national KSA rate.20 Community-based surveys using puriﬁed
tuberculin antigen skin tests have shown more people with
positive skin tests living in Makkah (20%) compared with other KSA
regions (10%).36 Accurate data on TB prevalence in pilgrims and
their role in contributing to the higher TB rates in the Makkah
region population are not available. Respiratory tract infections
spread rapidly and almost all pilgrims develop the ‘pilgrims
Table 1
Priority research studies for TB in pilgrims and KSA airport staff and healthcare workers in the Makkah region
Timing of study
enrolment
Aim of study Study design Study population
Pre-Hajj departure Study 1: To deﬁne the background burden of
active pulmonary TB (both drug-sensitive and
MDR-TB) in pilgrims
Cross-sectional study
Enrolment: any pilgrim able to produce a
sputum sample, irrespective of health
status
Pilgrims of all ages from selected high TB
and low TB burden countries
Pre-Hajj departure Study 2: To deﬁne the background burden of
active pulmonary TB (both drug-sensitive and
MDR-TB) in Jeddah airport staff and KSA
healthcare workers
Cross-sectional study
Enrolment: any staff member able to
produce a sputum sample, irrespective of
health status
KSA staff selected from airport and Hajj
health services
Pre-Hajj departure
and post-Hajj
follow-up
Study 3: To deﬁne the background burden of
LTBI in pilgrims
Study 4: To determine the acquisition of
Mycobacterium tuberculosis infection or active
TB during the Hajj period in pilgrims
(a) Cross-sectional study
(b) Longitudinal follow-up study
Pilgrims: adults from selected (a) high TB
burden countries, and (b) low TB burden
countries
Pre-Hajj and
post-Hajj follow-up
Study 5: (a) To deﬁne the background burden
of LTBI in Jeddah airport staff and KSA
healthcare workers
Study 6: (b) To determine the acquisition of M.
tuberculosis infection or active TB during the
Hajj period in Jeddah airport staff and KSA
healthcare workers
(a) Cross-sectional study
(b) Longitudinal follow-up study
KSA staff selected from airport and Hajj
health services
Pre-Hajj departure Study 7: Knowledge, attitudes of TB, and
knowledge of infection control practices of
pilgrims
Descriptive cross-sectional study Pilgrims of all ages from selected (a) high
TB burden countries, and (b) low TB burden
countries
Pre-Hajj Study 8: Knowledge, attitudes of TB, and
knowledge of infection control practices of
KSA staff selected from airport and Hajj health
services
Descriptive cross-sectional study KSA staff selected from airport and Hajj
health services
Pre-Hajj, during
Hajj, and post-Hajj
Study 9: Educational intervention study of
cough etiquette, infection control measures,
plus wearing masks of pilgrims
Randomized longitudinal case controlled
cohort study
Pilgrims of all ages from selected (a) high
TB burden countries, and (b) low TB burden
countries
Pre-Hajj, during
Hajj, and post-Hajj
Study 10: Educational intervention study of
cough etiquette, infection control measures,
plus wearing masks of KSA staff selected from
airport and Hajj health services
Randomized longitudinal case controlled
cohort study
KSA staff selected from airport and Hajj
health services
During Hajj Study 11: DS-TB prevalence study in pilgrims
in the community with respiratory symptoms
Cross-sectional study of pilgrims falling ill
with RTIs
Pilgrims seeking healthcare for RTIs at
clinics
During Hajj Study 12: MDR-TB prevalence study in
pilgrims in the community with respiratory
symptoms
Cross-sectional study of pilgrims falling ill
with RTIs
Pilgrims seeking healthcare for RTIs at
clinics
During Hajj Study 13: Proactive screening for TB and MDR-
TB in pilgrims admitted to hospitals in
Makkah irrespective of admission diagnosis
Cross-sectional study of pilgrims (a) on
general wards, and (b) in the ITU
Pilgrims admitted to hospitals
During Hajj Study 14: Proactive screening for TB and MDR-
TB in healthcare workers admitted to
hospitals in Makkah irrespective of admission
diagnosis
Cross-sectional study of HCWs (a) on
general wards, and (b) in the ITU
HCWs admitted to hospitals
During and after Hajj Study 15: To deﬁne M. tuberculosis
transmission patterns in the Makkah region
during the Hajj period
Biobank of mycobacterial isolates from the
Hajj studies analysed and compared with
data from the home countries of pilgrims
Molecular and phylogenetic analyses of
mycobacterial isolates
TB, tuberculosis; MDR, multidrug-resistant; KSA, Kingdom of Saudi Arabia; LTBI, latent tuberculosis infection; DS, drug-sensitive; RTI, respiratory tract infection; ITU,
intensive therapy/care unit; HCW, healthcare worker.
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upper or lower respiratory tract infection due to common viral or
bacterial pathogens, and they are treated empirically and may not
be proactively investigated for TB unless they are hospitalized.
The majority of research studies that have been published have
focused on the generic issue of acute bacterial and viral respiratory
tract infections,25–35 since they are associated with signiﬁcant
morbidity, and some associated with a high mortality may have
pandemic potential.25–27
6. Available data on TB in pilgrims
There have been no speciﬁc large-scale controlled studies to
ascertain the TB case load in pilgrims during the Hajj or Umrah.
Evidence of TB in pilgrims comes from clinical studies of causes of
hospital admissions during the Hajj. Alzeer et al. reported that of46 hospitalized patients with pneumonia during the 1994 Hajj, 13
(28%) had conﬁrmed TB.37 Madani and colleagues performed a
cross-sectional study of patients admitted to intensive care units
(ICU) in hospitals at Mina and Arafat during the 2003 Hajj.39
Pneumonia was found to be the most common cause of admission
in the 808 patients (19.7%), and sputum culture-conﬁrmed TB was
diagnosed in 5.9% of patients. Mandourah et al. performed a
prospective study of patients admitted to ICUs at 15 hospitals in
Makkah and Madinah over two consecutive Hajj years, 2009 and
2010.40 Of the 452 patients studied, pneumonia was the primary
cause of critical illness in 123 (27.2%) and TB was diagnosed in
4.9%. The presence of seriously ill pilgrims with TB in hospitals
probably represents the tip of the iceberg and indicates that a large
number may remain undiagnosed. A prospective cohort study of
pilgrims from Singapore showed them to be at high risk of
exposure to M. tuberculosis infection during their stay in the KSA.41
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the Hajj, 15 (10%) showed signiﬁcant positive responses at
3 months after their return to Singapore from Hajj. Whilst these
results are subject to issues in interpretation due to several
variables that affect the performance of the assay and the small
numbers of pilgrims studied, the data highlight the risk of
acquiring M. tuberculosis infection during the Hajj.
7. Deﬁning the burden of TB and M. tuberculosis transmission
risk in pilgrims and in KSA residents
The diagnosis and treatment of TB in pilgrims in the pre-Hajj
preparation stage, during their travel, and after their return home
from the pilgrimage, is a formidable challenge. Operational and
logistical issues in TB screening (rapidly mobile population of
pilgrims, the availability of imaging, sample collection, storage,
and processing equipment, and the availability of accurate and
rapid diagnostic tests for TB and for ruling out MDR-TB) have
hindered any large-scale TB cohort studies of pilgrims. Thus no
studies have proactively screened pilgrims or KSA residents for TB
using the latest in TB diagnostics such as the Xpert MTB/RIF
assay.42,43,18,44,45 The transmission dynamics of circulating drug-
sensitive and drug-resistant M. tuberculosis strains and their
phylogenetic relationships remain undeﬁned. The actual baseline
burden of active TB, MDR-TB, sub-clinical TB, and TB co-morbidity
with other communicable and non-communicable diseases in
pilgrims remains to be determined. The impact of the transmission
of drug-sensitive and drug-resistant strains of M. tuberculosis by
pilgrims to local resident KSA populations who interact with them
during the pilgrimage (and vice versa) also requires deﬁnition.
8. Opportunities for conducting priority TB research
The Hajj pilgrimage presents unique opportunities to conduct
priority research utilizing the formidable processes and structures
that are in place for handling millions of pilgrims.11 Prior to
departure, all pilgrims need to satisfy the pre-travel vaccination
requirements and apply for a visa. Pilgrims need to be linked with
speciﬁc Hajj travel agents who coordinate and supervise pilgrim
cohorts; these cohorts remain together during the entire Hajj
period until return. The KSA provides free healthcare to all pilgrims
during the Hajj, and a Hajj Command and Control Centre oversees
all infectious diseases issues. Planning for Hajj is meticulous and
coordinated.11 This includes numerous healthcare centres across
all pilgrimage routes, thousands of healthcare workers, numerous
mobile teams, and referral hospitals with inpatient and critical care
facilities. At all ports of entry to the KSA, public health ofﬁcials
are present to ensure compliance with the pilgrim health
requirements. There are holding areas and clinical examination
rooms speciﬁcally for health screening of pilgrims arriving at the
Hajj terminal of King Abdulaziz International Airport in Jeddah.
Using electronic data recording and surveillance systems, the
public health teams at the ports of entry continuously report to
the Command and Control Centre for Communicable Diseases at
the Hajj.11
Thus there are unique opportunities to conduct a range of
cohort and cross-sectional TB studies involving pilgrims and
susceptible KSA resident staff at points of pilgrim entry and
healthcare. These should be done at all stages of the Hajj, from the
pre-Hajj preparative stage to arrival in Jeddah, throughout all
stages of the Hajj in Makkah, and upon the return of the pilgrims
to their country of origin. Furthermore, new rapid diagnostic
platforms that can screen for all common causes of respiratory
tract infections (viral and bacterial, including TB) are being
developed,43,18 and opportunities now arise to deﬁne the relative
importance of each causal pathogen.9. Deﬁning burden, transmission risk, and the optimal
treatment, prevention, and control measures at the annual Hajj
pilgrimage
From a public health perspective, there is a need for a practical
and well-deﬁned strategy to minimize the risk of transmission of
M. tuberculosis and other respiratory tract pathogens at the Hajj
and Umrah pilgrimages. Thus aligning the research on TB to the
generic issue of respiratory tract infections will provide informa-
tion that will serve the greatest practical clinical need of infectious
diseases healthcare at the Hajj. Large-scale properly designed and
controlled studies on the prevention, diagnosis, epidemiology, and
management of TB in the context of the generic issue of respiratory
tract infections are required for the results to be applicable to the
large heterogeneous population of pilgrims. The evaluation of the
burden of active TB disease (including MDR-TB) and that of LTBI in
pilgrims and resident KSA staff, will require several cross-sectional
and longitudinal cohort studies to be performed pre-Hajj, during
the Hajj, and after the end of the Hajj (summarized in Table 1). The
results of these studies will allow the development of an accurate
evidence base, which will help in the formulation of international
recommendations by WHO collaborating centres for mass
gathering events and in the drawing up of guidelines for the
optimal surveillance, screening, transmission risk, treatment,
prevention, and control measures for TB at mass gathering events.
There are currently no speciﬁc recommendations to proactively
detect or prevent TB in pilgrims or KSA residents during the Hajj.
Whilst current KSA Ministry of Health guidelines focus on the use
of facemasks during the Hajj to prevent respiratory tract infections,
adherence to these measures has been difﬁcult to implement in
practice. There is a need for education campaigns to make the
pilgrims and the KSA public aware of TB, and to facilitate the
diagnosis of symptomatic cases. There is a need for case controlled
studies on the beneﬁts of educational interventions involving
simple hygiene and cough etiquette measures prior to departure
and during the Hajj period in reducing the transmission of
M. tuberculosis and other respiratory tract infections.
The screening of pilgrims from high TB burden countries before
travel could allow the detection and treatment of active pulmonary
TB cases and prevent the transmission of M. tuberculosis infection
to other pilgrims and KSA residents and Hajj staff. Basic screening
based on the ability to produce a sputum sample (irrespective of
health status) for examination with the Xpert MTB/RIF assay will
allow the detection of active or sub-clinical cases of pulmonary TB,
and of MDR-TB by proxy.43 Longitudinal cohort studies of pilgrims
from both high and low TB endemic areas with testing for LTBI
using interferon-gamma response assays before departure, during
the Hajj, and at 3 months after return from the Hajj, will provide
information on the risk of acquiring M. tuberculosis and the risk of
reactivation of LTBI during Hajj. This will also assist in deﬁning
transmission dynamics and patterns of both drug-sensitive and
drug-resistant strains of M. tuberculosis through the use of
molecular typing methods and whole genome sequencing directly
on patient sputum.43,18,44–47 Such studies will add to our
understanding of M. tuberculosis epidemiology and transmission
dynamics. Since the acquisition of M. tuberculosis infection during
the pilgrimage may not manifest as clinically active TB and may
result in LTBI, long-term follow-up studies of pilgrims and KSA
resident staff are required. In low TB burden countries, the
screening of pilgrims for LTBI before and after Hajj could identify
those cases that may beneﬁt from preventive therapy.
Non-communicable diseases are common causes of hospital
admission during the Hajj,48 and the opportunity to screen for TB
co-morbidity in pilgrims admitted for any cause of ill health should
be taken to identify sub-clinical or undiagnosed cases of TB.42
There is a need for proactive studies that screen for active TB
A. Zumla et al. / International Journal of Infectious Diseases 47 (2016) 86–9190among ill non-hospitalized and hospitalized pilgrims who can
produce a sputum sample to determine the prevalence of TB during
Hajj. The data could be stratiﬁed by country of origin and co-
morbidity with communicable and non-communicable diseases.
Since pilgrims are always on the move, the establishment of
well-equipped mobile health clinics with up-to-date laboratory
equipment, including molecular biology facilities, would be
required for the rapid diagnosis and identiﬁcation of all pathogens
causing respiratory tract infections, including TB and MDR-
TB.43,18,44 Establishing a central registry of information collected
at the Hajj, including data on genetic proﬁling and the drug
resistance of isolates, should be included as part of the agenda for
improving TB screening and services at the Hajj.
10. Conclusions
Accurate data on the actual burden of TB and transmission risk
associated with mass gatherings are scarce and unreliable due to
the small numbers studied and methodological issues. Developing
an accurate evidence base for optimal surveillance, screening,
transmission risk, treatment, prevention, and control measures for
TB at mass gathering events is an important priority and will go a
long way towards achieving the WHO post-2015 End TB Strategy
goals. The Hajj pilgrimage presents unique opportunities to
conduct priority research utilizing the formidable processes and
structures that are in place for handling millions of pilgrims.
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